ABSTRACT
Dysglycemia-based chronic disease describes a spectrum of metabolic risk, to biochemical risk (prediabetes), to early asymptomatic type 2 diabetes, to late type 2 diabetes with complications, particularly cardiovascular events, reflecting varying degrees of pancreatic ß-cell dysfunction, insulin resistance, inflammation, and organ dysfunction. Metabolic syndrome, insulin resistance syndrome, and polycystic ovary syndrome also fall within this dysglycemia spectrum.
